We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+30.48%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$1.86B
AUM Growth
+$307M
Cap. Flow
+$139M
Cap. Flow %
7.5%
Top 10 Hldgs %
55.49%
Holding
32
New
3
Increased
14
Reduced
5
Closed
3

Top Buys

Rank Stock Value
1
MYGN icon
Myriad Genetics
MYGN
+$73.2M
2
UTHR icon
United Therapeutics
UTHR
+$36.5M
3
NVRO
NEVRO CORP.
NVRO
+$31.5M
4
LMNX
Luminex Corp
LMNX
+$27.9M
5
TBPH icon
Theravance Biopharma
TBPH
+$19.9M

Top Sells

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$50.8M
2
SPPI
Spectrum Pharmaceuticals Inc
SPPI
+$24.5M
3
VSTM icon
Verastem
VSTM
+$16.7M
4
CSII
Cardiovascular Systems, Inc.
CSII
+$9.87M
5
FLXN
Flexion Therapeutics, Inc.
FLXN
+$5.62M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CPRX
26
DELISTED
Catalyst Pharmaceutical
CPRX
$22.8M 1.23%
6,044,719
– –
CARM
27
DELISTED
Carisma Therapeutics
CARM
$16.2M 0.87%
376,165
– –
INVA icon
28
Innoviva
INVA
$1.55B
$15.3M 0.82%
+1,002,675
New +$14.4M
ANIP icon
29
ANI Pharmaceuticals
ANIP
$1.8B
$8.08M 0.44%
142,943
– –
CSII
30
DELISTED
Cardiovascular Systems, Inc.
CSII
– –
-305,235
Closed -$9.87M
FLXN
31
DELISTED
Flexion Therapeutics, Inc.
FLXN
– –
-217,392
Closed -$5.62M
GWPH
32
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-364,300
Closed -$50.8M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q3 2018 Portfolio in Review

As of Q3 2018, Consonance Capital Management held 32 positions worth $1.86B, up 20% from $1.55B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Consonance Capital Management deployed $139M of net new capital in Q3 2018, opening 3 new positions and adding to 14 existing holdings. Its largest new stake was Myriad Genetics: 1,646,330 shares worth $75.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

On the sell side, the largest reduction was Spectrum Pharmaceuticals Inc, an estimated $24.5M trimmed.

  • Consonance Capital Management's largest Q3 2018 buy was Myriad Genetics: 1,646,330 shares worth $75.7M.
  • Consonance Capital Management added most to United Therapeutics in Q3 2018, an estimated $36.5M increase.
  • Consonance Capital Management's biggest Q3 2018 reduction was Spectrum Pharmaceuticals Inc, cutting an estimated $24.5M.
  • Consonance Capital Management fully exited GW Pharmaceuticals Plc American Depositary Shares in Q3 2018, selling an estimated $50.8M.
  • Consonance Capital Management's ten largest holdings make up 55% of its $1.86B portfolio in Q3 2018.
  • Consonance Capital Management opened 3 new positions and closed 3 in Q3 2018.
  • Consonance Capital Management's portfolio value rose 20% quarter-over-quarter to $1.86B.

Based on Consonance Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.